To explore patient and clinician experiences in the MACRO trial, focusing on the comparative effectiveness of endoscopic sinus surgery, clarithromycin, and placebo for chronic rhinosinusitis.
Approach:
Key Findings:
ESS showed greater improvement in patient-reported outcomes compared to clarithromycin or placebo, indicating its effectiveness.
Patients expressed varied motivations for trial participation, often seeking additional treatment options after previous failures.
Some patients viewed surgery positively, while others had concerns about risks, recovery, and the impact on their daily lives.
Postoperative experiences varied significantly, with some patients reporting rapid symptom relief and others facing complications.
Gastrointestinal symptoms were common among patients receiving clarithromycin, affecting their overall treatment experience.
Interpretation:
The MACRO trial's findings on ESS effectiveness could inform treatment discussions, but implementation faces challenges such as resource limitations, surgical capacity, and patient hesitancy regarding surgery.
Limitations:
Small sample size for qualitative interviews limits the generalizability of findings.
The context of the trial may not reflect broader patient populations or clinical settings.
Conclusion:
Effective communication and shared decision-making are essential for implementing ESS in clinical practice, alongside adequate health system resources to support surgical care.
Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.
